3. SEMINAR PLAN
INTRODUCTION
ANATOMY
SURGICAL ANATOMY
PANCREATIC TUMOURS
MODE OF PRESENTATION
PRE OPERATIVE WORK UP
VARIOUS SURGERIES/ SURGICAL VIDEOS
RECENT UPDATES
VARIOUS STUDIES/TRIALS
TAKE HOME MESSAGE
4. INTRODUCTION
Carcinoma of the exocrine pancreas accounts for
over 90 % of pancreatic tumors and remains an
unreduced oncologic challenge.
By definition,periampullary cancers arise within
2 cm of the major papilla in the duodenum.
Pancreatic adenocarcinoma accounts for 80% tumours
Most common GI malignancy after Ca colon
Least 5 years survival rate of 3 %.
Incidence rate is virtually identical to the
mortality rate
5. INTRODUCTION
Pancreatic cancer is a biologically aggressive tumor
from the onset .
Clinically queisent for a long time and hence present in
advanced state.
Only 20% of pancreatic cancers are operable for cure
Only 10% - 15% of pancreatic cancers are alive 12
months after the diagnosis
Average life of metastatic pancreatic cancer is 6 months
6. ANATOMY AND RELATION OF PANCREAS
Pancreas is a long retroperitoneal organ 15 to 20 cm in
length.
Weighs about 80 gms ,lies against L1 & L2 Vertebra.
It is arbitarily divided into HEAD,NECK BODY & TAIL
Head lies within the concavity of duodenum against second
lumbar vertebra and body overlies the first lumbar vertebra
7. Cuddles L Kidney
Tickles Spleen
Cradles Aorta
Opposes IVC
Dallies with
R Renal
Pedicle
Hugs the duodenum
Wraps the SMV
Hides behind peritoneum
Durman
8. BLOOD SUPPLY
PANCREATIC BRANCHES OF SPLENIC
ARTERY
SUPERIOR PANCREATICODUODENAL
ARTERY
INFERIOR PANCREATICODUODENAL
ARTERY
VENOUS DRAINAGE IS INTO SPLENIC
VEIN ,SUPERIOR MESENTERIC & PORTAL
VEIN
14. PANCREATIC DUCT
Main duct of Pancreas ( DUCT OF WIRSUNG )-
begins in tail of pancreas and runs on the posterior surface
of the body and head of pancreas.
HERRING BONE PATTERN
DIAMETER OF PANCREATIC DUCT
TAIL - 1 to 2 mm BODY - 2 to 3 mm
HEAD - 3 to 4 mm
Upto 5-6 mm of dilatation in a 70 yr old person is considered
normal.
Joins the bile duct in the wall of second part of duodenum to
form hepatopancreatic ampulla ( of Vater )
DUCT OF SANTORINI- begins in lower part of the head and
opens in to duodenum at minor duodenal papilla ( 6-8 cm from
19. INCIDENCE
Annual incidence 10 new cases per 100000 population
Lowest incidence – India and Middle East
Incidence increases steadily with age – with 80 % over 6th
decade of life
Male: Female ratio – 2:1
Pre and post menopausal women ratio is 2: 1
20.
21. ETIOLOGY & RISK FACTORS
HEREDITY - CANCER FAMILY SYNDROMES
CIGARETTE SMOKING
DIET – high intake of animal fat or meat.
OCCUPATIONAL
EXPOSURE TO RADIATIONS
GASTRIC SURGERIES
DIABETES MELLITUS/PERNICIOUS ANAEMIA/ CHRONIC
PANCREATITIS
22. Etiology – hereditary factors
Most of the pancreatic cancers are sporadic
7.8% of pancreatic cancer patients give a positive
family history
Hereditary syndromes
HNPCC
PZ syndrome
Ataxia Telangiectasia
Hereditary Pancreatitis
Familial Atypical Mole Melanoma syndrome
FAP
23. Etiology – Diabetes – Is it a cause or effect
Several studies have shown an increased
incidence of pancreatic cancer in diabetics
Diabetes is considered as an early symptom of
pancreatic cancer rather than being a cause
The diabetes of Pancreatic cancer is due to islet
cell dysfunction (Islet Amyloid polypeptide)
and not due to the destruction of the gland
24. Etiology – Chronic
Pancreatitis- Is it premalignant
The incidence of pancreatic cancer in
various entities of chronic Pancreatitis are
as follows
Hereditary Pancreatitis 25%
Tropical Pancreatitis 10%
Alcoholic Pancreatitis 5%
27. The tumours of the pancreas can be -
A. Non-Endocrineneoplasms
B. Endocrineneoplasms
TUMOURS OF THE PANCREAS
28. ENDOCRINE NEOPLASMS:
These are less common than non-endocrine
tumours and generally benign and sometimes
multiple. They includes:
Insulinoma
Glucogonomas
Others:
- Gastrinomas
- Somatostatatinomas
- Vipomas (Vasoactive Intestinal
Polypeptide)
common
31. Carcinoma - Pancreas
A, A cross-section through the head of the pancreas and
adjacent common bile duct showing both an ill-defined
mass in the pancreatic substance (arrowheads) and the
green discoloration of the duct resulting from total
obstruction of bile flow.
B, Poorly formed glands are present in densely fibrotic
stroma within the pancreatic substance; there are some
inflammatory cells
35. CLINICAL MANIFESTATIONS
It is unfortunate that malignant pancreatic cancers are
asymptomatic until local or systemic complication develop.
1. Obstruction to bile duct – Jaundice and pruritus
2. Obstruction to duodenum /stomach- Gastric outlet obstruction
3. Ulceration- Gastro intestinal haemorrhage
4. Infiltration of peripancreatic nerve roots produce pain
The onset of symptoms are insidious and progressive
Abdominal pain is usually post prandial and in epigastrium
Pain in upper back denotes retroperitoneal extension
36. Pancreatic Tumors in the Head
Tumors in the head may compress biliary ducts or pancreatic
ducts
37. SYMPTOMS AND SIGNS
CARCINOMA HEAD OF PANCREAS
1. WEIGHT LOSS – AVERAGING ABOUT 40%
2. OBSTRUCTIVE JAUNDICE-
3. DEEP SEATED ABDOMINAL PAIN
4. NON TENDER PALPABLE GALL BLADDER
5. CHOLANGITIS OCCURS IN 10 % OF PATIENTS
39. CARCI NOMA OF BODY AND TAIL
WEIGHT LOSS
DEEP SEATED PAIN
JAUNDICE- < 10 % OF PATIENT
SUDDEN ONSET OF DIABETES MELLITUS-25% OF
PATIENT
MIGRATORY THROMBOPHLEBITIS- OCCURS IN ABOUT
10% PATIENT
40. SYMPTOMS AND SIGNS
CARCINOMA OF AMPULLA OF VATER
1. Pain occurs less frequently – usually its colicky
2. Jaundice is often intermittent
3. Chills and fever – due to associated cholangitis
41.
42. Periampullary carcinoma
Any tumor within 2
cm from the duodenal
papilla is defined as
periampullary cancer.
Ca terminal PD
Distal CBD
Ampullary tumor
Duodenal tumor
43. Periampullary carcinoma
The individual components of peri
ampullary tumors differ in their
prognosis
Duodenal carcinoma
Ampullary carcinoma
CBD growth
Pancreatic ca
45. Clinical presentation
Mid epigastric pain radiating to back
Weight loss
Fatigue
Anorexia
Symptoms are vague and hence the delayed
presentation
46. Clinical presentation
Painless progressive jaundice 50-60%
Pruritus
Staetorrhea
Malabsorption
New onset of Diabetes in older patients
47. Clinical presentation
Jaundice is a late presentation in uncinate
process growth
Severe back pain indicate irresectablity and an
omnious sign
48. Physical findings
Physical findings are rare in pancreatic cancers
and their presence usually indicate advanced
stage
Resectablity is better when patient presents
with the classical painless progressive jaundice
56. CT
“Pancreatic protocol CT” is the gold
standard of investigation to stage the
disease and assess the operability
Triple phase CT
Closer cuts
Water used as an intraluminal contrast
Helical or multislice
57. CT
Focal or diffuse mass lesion which is hypo
dense (low attenuation) and hypo vascular
(poor contrast enhancement)
Dilated MPD and CBD
63. CT
Advantages
Available easily
Surgeons are familiar with CT
Excellent in giving details of operability
Disadvantages
May miss liver mets less than 1 cm
Miss peritoneal mets
Radiation
64. MRI
Advantages
No radiation
Avoids contrast
Single investigation that gives all the
information needed
Disadvantages
Cost & availability
Surgeons are unfamiliar
65. MRI
As it stand today CT is as good as MRI
Probably in the future, MRI is likely to be used
more frequently and may replace CT
67. Role of Biopsy
Tissue diagnosis is indicated in cases which
are found inoperable by imaging
Biopsy is indicated when Neoadjuvant
chemotherapy is planned
68. Why not a biopsy
May upstage the disease
Complications of biopsy
Has a very low negative predictive value
69. What biopsy
Ideally it should be
done under EUS
guidance
Targeted
No tumor seeding
No complications
like fistula
70. ERCP
Double duct sign
Not routinely done in
pancreatic
Cancer
Preop biliary drainage
Atypical lower CBD
obstruction
71. PET
It is useful in differentiating pancreatic cancer
from chronic Pancreatitis
Extra pancreatic disease
72. EUS
Ideal method to evaluate
lower CBD obstruction
Guided FNAC
Vascular invasion
EUS+FNAC= sensitivity of
90% and specificity of 95%
76. Staging
TX primary tumor cannot be assessed
T0 no evidence of primary tumor
T1 confined to pancreas
T1a less than 2 cm
T1b more than 2 cm
T 2 tumor extend to involve the bile
duct, duodenum and peripancreatic
tissue
T3 involvement of stomach, spleen, colon,
vessels
77. Staging
NX nodes cannot
be assessed
N0 no evidence
of nodes
N1 regional
nodes present
MX cannot be
assessed
M0 no metastasis
M1 distant
metastasis
78. Stage grouping
Stage I
T1 N0 M0
T2 N0 M0
Stage II
T3 N0 M0
Stage III
Any T N1 M0
Stage IV
Any T Any N M1
99. Pancreaticoduodenectomy
Walter Kausch was the first to successfully
perform pancreaticoduodenectomy in Berlin
1912
Allen Whipple popularized the operation in US
in 1935
Now this operation is called Kausch-Whipple
procedure
100. Pancreaticoduodenectomy
This operation suffered a very bad reputation
due to the operative mortality of over 25% and
morbidity of over 50%
Some authorities have even suggested that, this
operation be abandoned
105. PANCREATICODUODENECYTOMY- PYLORUS
PRESERVATIION
Incision- transverse subcostal / midline
Exploration/mobilization- kocherization
Cholecystectomy/division of the bile duct
Exposure of superior mesenteric vein
Division of duodenum
Division of gastroduodenal artery
Division of pancreatic neck
Dissection of uncinate process
Resected specimen-gallbladder,distal bile duct,2nd 3rd &4th part
of duodenum,proximal jejunum and head ,neck & uncinate
portion of pancreas
Reconstruction
108. Duodenum- preserving resection of the head of pancreas
Incision- transverse subcostal / midline
Exploration/mobilization- kocherization
Exposure of the pancreas
Dissection of the neck of pancreas
Resection along the CBD
Pancreatic remnant
Reconstruction
Bile duct anastomosis
Stenosis of the pancreatic duct
109. TOTAL PANCREATECTOMY
This involves the en bloc resection of
The whole of pancreas
The spleen
Distal half of stomach
Duodenum
Proximal 10 cm of jejunum
Gall bladder
Cystic and common bile duct
110. TOTAL PANCREATECTOMY
Incision- Transverse muscle-cuting incision
Exploration/mobilization- kocherization
Mobilization of duodenum/head of pancreas
Exposure of body and tail of pancreas
Dissection of the vessels- hepatic artery is traced
Mobilization of spleen and pancreas
Limited gastrectomy/pylorus preserving resection
Reconstruction – choledochojejunostomy/bowel anastomosis
112. REGIONAL PANCREATECTOMY
TYPE O – TOTAL PANCREATECTOMY
TYPE I -- RESECTION OF PORTAL VEIN SEGMENT
TYPE II a – Type I plus resection of proximal SMA
TYPE II b– Type I plus resection of celiac axis/hepatic artery
TYPE II c-- Type I plus resection of celiac axis & SMA
113. PANCREATIC ENDOCRINE DISEASE
Principles- whether tumour functioning or non-functioning
tumour benign or malignant
sporadic occurrence or part of MEN-I
Operative steps
IOUS- localization of islet cell tumours
delineation of proximity of tumour to pancreatic duct
demonstration of multiple tumours as part of MEN-I
ENUCLEATION- CUSA
DISTAL PANCRETECTOMY
114. PANCREATIC CANCER- LAPROSCOPIC STAGING
7.5 Mhz linear array transducer
Port-infraumbilical and right flank
Search for serosal deposit
Lesions on liver sampled/GB visualised
Transducer placed on porta hepatis
Look for dilataion of pancreatic duct
Position of tumour relative to pancreatic duct/portal vein
Lymphnodes more than 10 mm -significant
115. PANCREATIC TRANSPLANTATION
Suitable donors between 20 and 50 yrs
Pancreatic blood flow to be maintained- warm ischemia
Gland should be perfused with a cold preservation fluid-
hypertonic citrate solution
Pancreas removed avoiding damage to the gland– injection of
collagenase enzyme into the pancreatic duct under pressure.
Pancreas transported to processing centre-within four hours-
cold ischemia
116. RECENT UPDATES/CHANGING
APPROACH
Preop biliary drainage
Preop imaging, CT vs. MR vs. EUS
Role of biopsy
Diagnostic laparoscopy
PJ vs. PG
Classical Whipple vs. PPPD
Vascular resections
Extended lymphadenectomy
Drainage
117. Controversies
Role of octreotide
Order of reconstruction
Adjuvant therapy
Palliative resections
Palliative bypass
118. Preop biliary drainage
For
Reduce the mortality and morbidity of surgery
Improves the liver function
Reduces the bleeding
Improves the nutrition
Buys time
119. Preop biliary drainage
Against
Does not reduce the mortality and morbidity
More infectious complications
It takes 6 weeks for the improvement of hepatic
microsomal functions
Makes the duct small and fibrotic – adds to
technical difficulty
120. Preop biliary drainage -
consensus
Indicated
Cholangitis
Impending renal failure
Surgery is likely to be delayed
Bilirubin of more than 20 mg%
Nutritionally very poor
Neoadjuvant chemotherapy is planned
121. Preop biliary drainage -
consensus
Routine preop biliary
drainage is not
recommended and there is
no evidence to support it
122. Diagnostic laparoscopy
30% of patients found operable by imaging are
found to have small liver mets or peritoneal
mets, on diagnostic laparoscopy
Warshaw et al
123. Diagnostic laparoscopy
With the advent of high quality
CT, Helical and Multislice,
occult peritoneal and liver
metastasis are documented in
only 10% in some series
124. PJ vs. PG
Merits of PG
Stomach is in proximity to pancreatic stump
Better vascularity
Acid in stomach inactivates enzymes
Absence of enterokinase
Even if leak occurs the enzymes are not activated
and hence fatal bleeding do not occur
125. PJ vs. PG
Two randomized controlled trials fail to
demonstrate superiority of one method over
the other
Dilated duct, texture of pancreas and surgeon’s
experience are more important than the viscera
used for drainage
126. Classical Vs PPPD
PPPD is oncologically as radical as classical
whipple except for tumors encroaching on the
D1 and pylorus
RCTs have failed to show any significant
benefit of PPPD over classical whipple
127. Vascular
involvement
Resection of SMV is
accepted provide it
enables to perform R0
resections
Involvement of SMA is
a contraindication for
resection
128. Extended
lymphadenectomy
Studies have shown
that extended
lymphadenectomies
can be done with
acceptable morbidity
Extended
lymphadenectomy do
not improve the
survival
129. Octreotide
There have been totally six RCT across the
Atlantic, three from Europe ( Buchler et al, Beger
et al , Pedrazolli et al) and three from US ( Yeo et
al, Sarr et al and Lowy et al)
The European trials favor use of octreotide and the
American trials do not favor
Recently published meta analysis of these trials
have shown a benefit f octreotide in reducing the
complications
131. Adjuvant therapy
The ESPAC trial has shown that the only
factor that positively affect the long term
survival is administration of adjuvant
chemotherapy
Ideally all patients undergoing surgery for
cancer pancreas should be given adjuvant
chemotherapy
133. Palliative resections – Is it
acceptable
Palliative resections and palliative bypass has
the same survival
Hence palliative resections are not accepted
134. Palliative resections
The series from John Hopkins has shown
survival benefits in R1 and few cases of R2
Whipple
135. Palliative resections
The consensus is that one should not willfully
perform a palliative resection, and the aim of
the surgeon should always be a R0 resection
136. Palliative bypass
Operative palliation is not the standard of care
for a patient with inoperable Ca pancreas with
obstructive jaundice
Endoscopic palliation is the treatment of
choice
137. Palliative bypass
A selected group of patients with good
performance status
Patients who are found to be inoperable on
the table
Endoscopy facilities not available or not
possible for technical reasons
138. Palliative bypass
Options of by-pass
Choledochojejunostomy ( Loop or Roux en Y)
Cholecystojejunostomy
Hepaticojejunostomy
139. Palliative bypass-prophylactic GJ
The current recommendation is to perform a
prophylactic GJ along with the biliary bypass
even if there is no gastric outlet obstruction
140. Laparoscopy in palliation
Depending on the expertise of the surgeon,
procedures can be done with laparoscopy
141. Palliation of pain
Neurolysis ( 20 ml of absolute alcohol injected
on either side of the celiac axis to destroy the
celiac ganglia)
At laparotomy
CT guided
EUS guided
Thoracoscopic splanchnectomy
143. TAKE HOME MESSAGE
Survival rate of patients after the establishment of diagnosis is
very dismal.
Surgical resection if possible ,is the only curative treatment but
it can play a role only in very small percentage of cases
Post surgery five year survival rate is least in pancreatic
malignancy.tive
Newer approaches are less radical and more effective
Concept of regional pancreatectomy has increased poet op
survival period
Survival can be further increased by- early detection
- avidance of surgery in presence of metastasis
- operative technique with avoidance of local spillage
- avoiding preoperative blood transfusion.
144. REFERENCES
BAILEY & LOVE’S- SHORT PRACTISE OF
SURGERY
SABISTON TEXTBOOK OF SURGERY
MASTERY OF SURGERY by Fischer
OXFORD TEXTBOOKOF SURGERY
MAINGOTS ABDOMINAL OPERATION
MAYO CLINIC GI SURGERY
CANCER PRINCIPLES- De Vita
SURGERY BY CORSON
RECENT ADVANCES- WOLTERS KLUWER
RECENT ADVANCES- RSG